Catalysts
Catalyst Setup
The next six months hinge on whether the 21 May 2026 trading update and 4 August 2026 H1 results keep FY2026 guidance credible after the InnovaMatrix reset. The calendar is thin outside those two hard company dates: there is no visible transaction, refinancing cliff, or scheduled regulatory ruling that independently resets the stock. The market is likely watching four proof points: ex-InnovaMatrix organic growth versus the 5-7% FY2026 guide, adjusted operating margin of at least 23%, cash conversion after higher growth capex, and whether Unomedical/FDA and InnovaMatrix reimbursement risk stay contained. All financial figures use $; LSE tape levels are quoted in pence because the local share price trades in GBp.
Hard-Dated Events
High-Impact Catalysts
Next Hard Date Days Away
Signal Quality / 5
The useful read is not that Convatec has a crowded catalyst tape. It has a narrow event path: 21 May tests whether management can hold the guide, 4 August tests whether the numbers actually support it, and the rest is soft evidence around quality, reimbursement, and sponsorship.
Ranked Catalyst Timeline
Impact Matrix
Next 90 Days
The first full P&L and cash-flow test is just outside the strict 90-day window: H1 results are scheduled for 4 August 2026, 94 days from the current date of 2 May 2026. That is the better underwriting event than the May update, but the May update sets the tone for whether investors should expect an ordinary H1 or a guide-risk H1.
What Would Change the View
The debate would change fastest if H1 2026 shows ex-InnovaMatrix organic growth tracking the 5-7% guide, adjusted operating margin still on a path to at least 23%, and cash conversion holding after all capex rather than only under the new FCFE definition. That would strengthen the bull case that Accelerate is a real compounding path, not a product-cycle promise. The bear case gains force if May or August exposes a weak H2 bridge, renewed receivables/capex strain, or any Unomedical escalation that threatens Infusion Care's growth engine. The variant-perception item is InnovaMatrix: stabilizing near the reset guide plus 2026 evidence publication would make the reimbursement issue look contained, while further impairment or evidence slippage would damage trust in management's product-specific underwriting. Technicals matter as a forcing function: a reclaim of 246p would show sponsorship returning, while a confirmed break below 209.8p would imply the market is not waiting for formal guide failure.